Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY) and Selecta Biosciences (SELB).
Incyte (INCY)
Oppenheimer analyst Jay Olson assigned a Buy rating to Incyte today and set a price target of $121.00. The company’s shares closed last Wednesday at $89.74.
According to TipRanks.com, Olson has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.3% and a 39.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $103.73.
See today’s analyst top recommended stocks >>
Selecta Biosciences (SELB)
Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on Selecta Biosciences today and set a price target of $2.00. The company’s shares closed last Wednesday at $2.48.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 9.2% and a 44.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Selecta Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $7.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
